POT1 and cancer: One chosen ligand, pyridostatin (PDS; 1), was previously shown to inhibit binding of the shelterin component, POT1, to human telomeric DNA (31) as well as to induce DNA damage at G4 motifs in human cancer cells (see Figure 2A for structure) (32).